Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Inclusion Criteria:

Be willing and able to provide written informed consent/assent for the trial.
Capability to understand and comply with the protocol and signed informed consent document.
Be ≥ 18 years of age on day of signing informed consent.
Have measurable disease based on RECIST 1.1.
Histologically confirmed, non-metastatic adenocarcinoma of the prostate
Prostatectomy with extended lymph node dissection planned as primary therapy
10 year or longer life expectancy based on other co-morbidities
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.

Any one of the following three high risk features:

Gleason grade > 8-10
PSA > 20 ng/ml
Clinical stage T3a (resectable)
No evidence of metastases .
No other diagnosis of malignancy (with exception of non-melanoma skin cancer or a malignancy diagnosed ≥5 years ago).
Male subjects of childbearing potential must agree to use an adequate method of contraception. Contraception, starting with the first dose of study therapy through the time of surgery. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
Demonstrate adequate organ function, all screening labs should be performed within 30 days of treatment initiation.